Filament Health, a subsidiary of Rhelion Life Sciences, has signed an agreement to supply its patented psilocybin drug candidate PEX010 to Epsylon ASBL for Belgium's first compassionate use program allowing patients with treatment-resistant depression access to psilocybin outside clinical trials. The program, supported by Psychedelic Society Belgium, awaits approval from Belgian health authorities and aims to provide regulated access to psilocybin treatment. This marks a significant step in expanding legal access to psychedelic therapies in Europe, with Filament providing regulatory support and standardized pharmaceutical-grade psilocybin doses. The program is led by Dr. Daniel Souery and represents a potential breakthrough for patients with serious unmet medical needs.
Rhelion Life Sciences' subsidiary Filament Health is noted here with Pluang's Health-sector market data for context. Of 150 priced US Health stocks on Pluang, 93 rose and 46 fell today. Notable movers include HRTX at USD 0.39 with a 3.05% gain, MRVI at USD 6.91 down 2.26%, and MESO at USD 13.66 down 2.08%. This snapshot is as of Oct 16, 2026 19:01 WIB.
Whole Lotta Dank, a Canadian cannabis brand platform, has launched its first brand, Dank Pack, debuting with Blueberry BBL available across Alberta. The company is expanding its portfolio with over 20 SKUs under regulatory review and is actively seek...
Nasdaq announced that trading in CN Healthy Food Tech Group Corp.'s common stock and warrants will resume on October 19, 2026, after being halted since October 1, 2025. The resumption marks the end of a year-long trading suspension, allowing investor...
David Solomon, CEO of Goldman Sachs, has been appointed as the new chair of The Business Council, taking over from Brian Cornell, Executive Chair of Target Corporation. This leadership change comes at a critical time as the Council addresses challeng...
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, expanding at a CAGR of 6.15%. Growth is fueled by advances in biologics, AI-driven drug discovery, specialty drugs, and manufacturing i...
SEDA Experts LLC has appointed Noor Ul Islam as Managing Director, enhancing its capabilities in risk management and securities practices. With nearly 30 years of experience at major financial institutions like Citibank and Barclays, Islam brings dee...
